The Jenex Corporation Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"). Jenex would like to announce the grant of stock options to directors, officers and consultants of the Company to purchase up to an aggregate of 1,500,000 common shares of the Company pursuant to the Company's share option plan. The options are exercisable for a period of five years at a price of $0.11/share. About Jenex: Jenex is a progressive medical device technology...
2017-10-06 6:19 PM EDT
The Jenex Corporation Terminates Exclusive License Agreement with Luminar Media Group Inc.
Toronto, Ontario--(Newsfile Corp. - October 2, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announced that it has formally terminated its exclusive agreement dated October 31st, 2016 to distribute TherOZap™ globally outside of Canada (the "Agreement") with Luminar Media Group Inc. ("Luminar"), for reasons of non-performance of fees payable as outlined in the Agreement. Jenex may in the future consider a...
2017-10-02 5:33 PM EDT
The Jenex Corporation Announces Approvals of Equity Financing & Move to TSX Venture Exchange (TSXV)
Toronto, Ontario--(Newsfile Corp. - September 19, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, today announced that it has completed a non-brokered private placement (the "Private Placement Financing") of 6,350,000 Units ("Units") of the Company at a price of $0.05 per Unit for gross proceeds of $317,500 and has received final stock exchange approval therefor. The Units were oversubscribed and approval was granted...
2017-09-19 8:00 AM EDT
Jenex Reports Expected Date of Test Results for TherOZap(TM) at Inactivating the Zika Virus
Toronto, Ontario--(Newsfile Corp. - September 14, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap™ at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October. Techna Institute has informed Jenex that additional...
2017-09-14 4:30 PM EDT
Jenex is Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - August 30, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). At the request of IIROC, The Jenex Corporation wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Jenex: Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their...
2017-08-30 12:56 PM EDT
The Jenex Corporation Announces Conditional Acceptance of Reactivation from NEX to TSX Venture Exchange, TherOZap(TM) Testing and ISO 13485:2003 Update
Toronto, Ontario--(Newsfile Corp. - August 17, 2017) - The Jenex Corporation (NEX: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has obtained the conditional acceptance of the TSX Venture Exchange (the "Exchange" or "TSXV") in respect of its application for reactivation to the TSXV as a Tier 2 Life Science Issuer (the "Graduation"). The Graduation is conditional upon satisfaction of the following conditions on or before November...
2017-08-17 8:57 AM EDT
The Jenex Corporation Completes $317,500 Oversubscribed Non-Brokered Private Placement with Insider Participation
Toronto, Ontario--(Newsfile Corp. - June 21, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its May 29, 2017 announcement, (The Jenex Corporation Announces Equity Financing with Insider Participation), it has completed, subject to receiving final acceptance from the TSX Venture Exchange (the "TSXV"), an oversubscribed non-brokered private placement (the "Financing") of 6,350,000...
2017-06-21 4:26 PM EDT
The Jenex Corporation Announces Equity Financing with Insider Participation
Toronto, Ontario--(Newsfile Corp. - May 29, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announced that it intends to complete a non-brokered private placement (the "Private Placement Financing") of up to 5,000,000 units ("Units") of the Company at a price of $0.05 per Unit for gross proceeds of up to $250,000 subject to regulatory and stock exchange approval. There is no minimum offering amount. Each Unit will...
2017-05-29 4:18 PM EDT
Jenex Finalizing Protocol to Test TherOZap(TM) Against the Zika Virus with University Health Network
Toronto, Ontario--(Newsfile Corp. - May 23, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, is pleased to report that after extensive collaboration with Techna Institute and University Health Network ("UHN"), the Company is now in the final stages of designing a testing protocol for the patent pending TherOZap™ device to determine its effectiveness at inactivating the Zika virus. Through this collaboration Jenex and UHN...
2017-05-23 7:00 AM EDT
Jenex to Test TherOZap(TM) Working Prototype and Topical Cannabidiol Oil Against the Zika and West Nile Viruses
Toronto, Ontario--(Newsfile Corp. - April 18, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, would like to report the testing of a topical cannabidiol ("CBD") oil from hemp with Jenex's platform technology, including Jenex's TherOZap™ device. The topical cannabidiol oil will be included in the lab tests, to be conducted through University Health Network and coordinated through Techna Institute at UHN located in Toronto,...
2017-04-18 9:17 AM EDT
Jenex Completes Design of TherOzap(TM) Working Prototype and Signs Service Agreement with University Health Network to Initiate Testing Against the Zika and West Nile Viruses
Toronto, Ontario--(Newsfile Corp. - April 7, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), a progressive medical device technology company, would like to report that the design of the working prototype for the patent pending TherOZap™ is now complete. Images of the working prototype can be viewed here: www.therozap.com. Jenex has optimized the features on the TherOZap™ working prototype device to determine its effectiveness at inactivating both the Zika virus and...
2017-04-07 9:16 AM EDT
The Jenex Corporation Announces Shares For Debt Closing
Toronto, Ontario--(Newsfile Corp. - April 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company") announces that it has issued 18,341,302 common shares to settle $917,065 of debt owing by the Company. The shares are subject to a hold period which expires on August 6, 2017. This is the first of two closings of the debt settlement described in the Company's news release of February 13, 2017. The TSX Venture Exchange has approved the issuance of an additional 16,008,634 common...
2017-04-06 4:18 PM EDT
Jenex Provides Update on TherOZap(TM) Working Prototype, and InterceptCS
Toronto, Ontario--(Newsfile Corp. - March 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). Jenex would like to report that the development of the working prototype for the patent pending TherOZap™ is scheduled for completion prior to the end of March 2017. The Company has finalized the optimal components and features for the working prototype. As previously reported Jenex expects to test the working prototype to determine its effectiveness at inactivating both the...
2017-03-06 8:20 AM EST
Jenex Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - February 27, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). At the request of IIROC, The Jenex Corporation wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Jenex: Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their...
2017-02-27 2:18 PM EST
Jenex Announces Proposed Debt Settlement
Toronto, Ontario--(Newsfile Corp. - February 13, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Corporation") announced today that, further to its news release of November 18, 2016, Jenex proposes to issue 34,349,937 common shares in settlement of $1,717,496.93 of debt owed by the Corporation. The common shares are to be issued at a price of $0.05 each and will be subject to a hold period expiring four months plus a day after closing. The debt to be settled includes $600,000 of...
2017-02-13 8:00 AM EST
Jenex Provides Update on Next Generation Technology, TherOZap(TM) to Test Against the West Nile Virus and Zika Virus
Toronto, Ontario--(Newsfile Corp. - January 24, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). Jenex would like to report that the development of the working prototype for the patent pending TherOZap™ is progressing well and expected to be completed in 4 to 6 weeks. On December 8 2016, the Company announced the development of its TherOZap™ device utilizing proprietary features would be tested against both the Zika and West Nile Virus. Jenex is now in the final stages...
2017-01-24 9:17 AM EST
Jenex to Test Next Generation Technology, TherOZap(TM) Against the Zika Virus and West Nile Virus
Toronto, Ontario--(Newsfile Corp. - December 8, 2016) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"), Jenex to test next generation technology, TherOZap™, against the Zika Virus and West Nile Virus. Rob Fia, CEO and Chairman of Jenex, reports the Company will undergo testing of its patent pending technology, TherOZap™, against the Zika and West Nile virus. Jenex has engaged an independent lab and internationally recognized health care network to conduct the tests. The tests...
2016-12-08 9:37 AM EST
Jenex Announces TherOZap(TM), the Company's Next Generation Thermal Therapy Insect Device and Proposed Share for Debt Settlement Terms
Toronto, Ontario--(Newsfile Corp. - November 18, 2016) - The Jenex Corporation (TSXV: JEN.H) ( "Jenex", or the "Company"). Jenex announces TherOZap™, the name of the Company's next generation thermal therapy insect device, and debt settlement terms. TherOZap™ will utilize advanced technology to provide relief to sufferers of insect bites and stings. Rob Fia, CEO & Chairman comments: "TherOZap™ will continue to provide the quick relief from pain, itch and stings caused by insect bites that our...
2016-11-18 8:39 AM EST
IIROC Trade Resumption - The Jenex Corporation
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2016) - Trading resumes in: Company: The Jenex Corporation
2016-11-03 9:33 AM EDT
Jenex Signs Exclusive License Agreement with Luminar Media Group Inc. for USD $250,000 for Jenex's Next Generation Thermal Therapy Insect Device
Toronto, Ontario--(Newsfile Corp. - November 3, 2016) - THE JENEX CORPORATION (TSXV: JEN.H) ("Jenex" or the "Corporation"), Rob Fia, CEO and Chairman of Jenex, reports the Corporation has entered into an exclusive license agreement (the "License") with Luminar Media Group Inc. of Aventura, Florida to market Jenex's next generation thermal therapy insect device (the "Device"). Luminar has an extensive contact base with Over the Counter ("OTC") retail distribution channels in the US. Europe and...
2016-11-03 8:00 AM EDT